Source link : https://www.newshealth.biz/health-news/continuous-parkinsons-disease-therapy-wins-fda-nod/
The FDA approved a subcutaneous 24-hour continuous infusion of foscarbidopa and foslevodopa (Vyalev) for advanced Parkinson’s disease, AbbVie announced Thursday. Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson’s treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous 24-hour-a-day infusion of a levodopa-based therapy to treat motor fluctuations […]
Author : News Health
Publish date : 2024-10-17 19:05:39
Copyright for syndicated content belongs to the linked Source.